Neurizon Therapeutics Limited has released a press release.
Neurizon Completes Entitlement Offer
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Global Trademark Protection Secured Across Key Markets
- Regulatory and Development Update
- New Funding Secured for HEALEY ALS Platform Trial
- Equity Raising Presentation
- Trading Halt
Later from Neurizon Therapeutics
- Neurizon secures $6million R&D Tax Incentive Rebate
- Appendix 4C & Quarterly Update
- Appendix 4D - Half-year Financial Report - 31 December 2025
- Neurizon Initiates Dosing in HEALEY ALS Platform Trial
- Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics